Abstract

Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TILs) has shown clinical responses in the treatment of metastatic melanoma. Improvement in the persistence of TILs is an area of ongoing investigation. Emerging data has demonstrated that levels of circulating metabolites significantly affect T cell function and survival in multiple pre-clinical models of ACT. However few studies have interrogated the circulating metabolome in patients undergoing ACT. We aimed to investigate changes in the serum metabolome in patients with metastatic melanoma undergoing ACT with TILs.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.